Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 10
2004 10
2005 18
2006 11
2007 11
2008 24
2009 18
2010 28
2011 23
2012 17
2013 15
2014 18
2015 24
2016 26
2017 19
2018 28
2019 29
2020 27
2021 25
2022 25
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Preface.
Manai M, Boussen H, Cristofanilli M. Manai M, et al. Among authors: cristofanilli m. Int Rev Cell Mol Biol. 2024;384:xiii-xiv. doi: 10.1016/S1937-6448(24)00060-1. Int Rev Cell Mol Biol. 2024. PMID: 38637102 No abstract available.
Inflammatory breast cancer: Epidemiologic data and therapeutic results.
Boussen H, Berrazaga Y, Sherif Kullab, Manai M, Berrada N, Mejri N, Siala I, Levine PH, Cristofanilli M. Boussen H, et al. Among authors: cristofanilli m. Int Rev Cell Mol Biol. 2024;384:1-23. doi: 10.1016/bs.ircmb.2023.10.003. Epub 2024 Feb 6. Int Rev Cell Mol Biol. 2024. PMID: 38637094 Review.
Pharmacological suppression of the OTUD4-CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, Chi JJ, Zeng L, Lee JY, Xue Y, Lu X, Cristofanilli M, Gradishar WJ, Henry CJ, Gillespie TW, Bhave MA, Kalinsky K, Fu H, Bahar I, Zhang B, Wan Y. Zhu Y, et al. Among authors: cristofanilli m. J Clin Invest. 2024 Mar 26:e176390. doi: 10.1172/JCI176390. Online ahead of print. J Clin Invest. 2024. PMID: 38530357 Free article.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. Among authors: cristofanilli m. J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940. Online ahead of print. J Clin Oncol. 2024. PMID: 38513188
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: cristofanilli m. Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. Breast Cancer Res. 2023. PMID: 37784176 Free PMC article.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Nicolò E, Tarantino P, D'Ecclesiis O, Antonarelli G, Boscolo Bielo L, Marra A, Gandini S, Crimini E, Giugliano F, Zagami P, Corti C, Trapani D, Morganti S, Criscitiello C, Locatelli M, Belli C, Esposito A, Minchella I, Cristofanilli M, Tolaney SM, Curigliano G. Nicolò E, et al. Among authors: cristofanilli m. Oncologist. 2024 Jan 5;29(1):75-83. doi: 10.1093/oncolo/oyad212. Oncologist. 2024. PMID: 37548439 Free PMC article. Review.
396 results